On CNBC's “Mad Money Lightning Round,” Jim Cramer said, “This is a very speculative situation,” when asked about ADMA Biologics, Inc. ADMA. “Any time there's immunity-compromised patients, there's some big money down the road,” he added.
On Aug. 8, ADMA Biologics reported better-than-expected second-quarter financial results and raised its FY24 and FY25 revenue guidance above estimates.
The company reported quarterly earnings of 13 cents per share which beat the analyst consensus estimate of 7 cents per share. The company reported quarterly sales of about $107.2 million which beat the analyst consensus estimate of $86.4 million.
“This is one of those situations that is very difficult,” Cramer on MP Materials Corp. MP. “If they don't pull out of the tailspin of losses, then it just doesn't matter.”
On July 25, Marine Prods posted better-than-expected sales for its second quarter. Marine Prods reported quarterly earnings of 14 cents per share which met the analyst consensus estimate. The company reported quarterly sales of $69.55 million which beat the analyst consensus estimate of $65.35 million.
When asked about Delcath Systems DCTH, he said, “There's no investing. At this point, it is speculating.”
On Aug. 28, Delcath Systems announced positive results from independent study on liver-directed therapy for uveal melanoma patients.
Price Action:
- ADMA Biologics shares fell 0.1% to settle at $17.22 on Thursday.
- MP Materials shares gained 3.2% to close at $12.90.
- Delcath Systems shares gained 1.2% to close at $10.77.
Read Next:
Image: Shutterstock
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
